CymaBay Focused On PBC With Seladelpar, Wants Partner For NASH

 
• By Joseph Haas
scientists doing lab research on digital screen
CymaBay's PBC candidate shows fibrosis, inflammation, liver marker benefits

More from Clinical Trials

More from R&D